Plasma Interleukin-8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer

In vivo activity of nanoliposomal irinotecan was validated in an orthotopic nude murine model expressing TAK1-specific shRNA. Differential expression profiling revealed the gene coding for interleukin-8 as the most significantly downregulated in shTAK1 pancreatic cancer cell lines.